Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Liver fibrosis is a common response to chronic liver injury due to multiple etiologies and plays a crucial in the progression of chronic liver disease to cirrhosis, hepatocellular carcinoma, and other liver-related clinical outcomes. Currently, available treatments to block liver fibrosis are design...
Saved in:
| Main Authors: | Xiangchang Zeng, Deliang Huang, Zhibin Zhu, Qingxian Cai, Yang Yang, Hongzhou Lu, Jun Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1574385/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fusion protein of retinol‐binding protein and albumin domain III reduces liver fibrosis
by: Hongsik Lee, et al.
Published: (2015-04-01) -
Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis
by: Chiao-Yin Sun, et al.
Published: (2025-01-01) -
Current strategies for targeted therapy of liver fibrosis
by: D. V. Garbuzenko
Published: (2022-10-01) -
Drug treatment strategies for secondary lymphedema
by: Fu Yongda, et al.
Published: (2025-07-01) -
Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)